title: Phase II evaluation of bryostatin-1 in metastatic melanoma.
abstract: In this phase II study we assessed the efficacy of bryostatin-1 (NSC 339555) in metastatic melanoma patients when given intravenously either once a week at a dose of 25 microg/m2 per day over 24 h for 3 weeks or at 40 microg/m2 per day over 72 h every 2 weeks. Treatment courses were repeated every 4 weeks. Patients who had received one prior chemotherapy regimen for advanced melanoma, with or without biotherapy, were randomized to one or the other bryostatin-1 dose schedules until 12 patients were registered to each arm. Because there was one confirmed response among the 12 patients who received the 72 h dose schedule, 25 more patients were added to that arm. No prophylactic medications were given. Objective tumour measurements were used to assess the efficacy of the regimen. The National Cancer Institutes common toxicity criteria were used to grade reactions. In total, 49 patients with metastatic melanoma, none having symptomatic brain metastasis, were studied. Of these, 12 patients received the 24 h bryostatin-1 regimen, while the remaining 37 received the 72 h regimen. One patient receiving the 72 h regimen had a partial response lasting over 7 months. Muscle pain occurred in over 90% of the patients and was the dose-limiting side effect of the 72 h regimen. Grade 3/4 nausea and vomiting were more common on the 24 h regimen than on the 72 h one (35% versus 5% of patients). There was no therapy-related thrombocytopenia. Neutropenia was mild and mainly limited to patients receiving the 72 h regimen. Bryostatin-1 has limited activity against melanoma when given by 72 h intravenous infusion.
authors.affiliation: Department of Melanoma/Sarcoma Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
authors.forename: A Y
authors.initials: AY
authors.lastname: Bedikian
authors.forename: C
authors.initials: C
authors.lastname: Plager
authors.forename: J R
authors.initials: JR
authors.lastname: Stewart
authors.forename: C A
authors.initials: CA
authors.lastname: O'Brian
authors.forename: S K
authors.initials: SK
authors.lastname: Herdman
authors.forename: M
authors.initials: M
authors.lastname: Ross
authors.forename: N
authors.initials: N
authors.lastname: Papadopoulos
authors.forename: O
authors.initials: O
authors.lastname: Eton
authors.forename: J
authors.initials: J
authors.lastname: Ellerhorst
authors.forename: T
authors.initials: T
authors.lastname: Smith
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015153:Blotting, Western; D054713:Bryostatins; D004305:Dose-Response Relationship, Drug; D015536:Down-Regulation; D005260:Female; D006801:Humans; D007783:Lactones / Q000627:therapeutic use*; D018942:Macrolides; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D020033:Protein Isoforms; D011493:Protein Kinase C / Q000096:biosynthesis / Q000378:metabolism; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D054713:Bryostatins; D007783:Lactones; D018942:Macrolides; D020033:Protein Isoforms; C046785:bryostatin 1; D011493:Protein Kinase C